Daniel Feigelson has represented clients in a wide variety of fields and in many contexts.
Mr. Feigelson has conducted patent portfolio and freedom-to-operate analyses for venture capital funds, for medical device and pharmaceutical formulation companies seeking investments, and for pharmaceutical companies contemplating the in-licensing of molecules and the further development thereof. He has also helped clients consider their options and formulate responses to cease-and-desist letters, including the preparation of declaratory judgment complaints, and has provided opinions to a major gemstone manufacturer on the viability of potential patent infringement suits.
Daniel Feigelson has experience coordinating multi-national approaches to patent defense and enforcement with in-house and foreign outside patent and litigation counsel. He has worked closely with world-class experts in the areas of pharmaceutical formulations and crystalline polymorphism, preparing affidavits for use in adversarial proceedings. He has also advised clients regarding pharmaceutical patent term extensions in Israel.
Originally trained as a chemist, Mr. Feigelson enjoys preparing opinions on the patentability of new molecules and the drafting and prosecution of associated patent applications, as well as freedom-to-operate opinions for pharmaceutical and agrochemical companies. He has represented individuals and small businesses before both the U.S. and Israel Patent Offices, preparing and prosecuting patent applications for pharmaceutical formulations and for new medical, veterinary and agricultural uses of known enzymes and other compounds, including procuring patents that were acquired by larger companies, for products that eventually received FDA approval. He has also worked extensively for a leading innovative drug manufacturer, developing both patent and non-patent strategies to defend market positions for blockbuster drugs, as well as assessing the potential impact of draft patent legislation and proposing alternative statutory language.
Additional work in the chemical field has included drafting and prosecuting applications pertaining to water treatment techniques, synthetic methods, semiconductor etching, and separation membranes. Mr. Feigelson has also drafted applications in the fields of nanomaterials, information technology and endotrachial tubes, and has prosecuted applications for arterial stents and other medical devices. He has extensive experience with Israel patent opposition proceedings, representing clients in cases involving optics for infrared imaging, missile construction, security fence technology and drip irrigation equipment, and has been involved with oppositions before the EPO. He has also served as a consulting expert on Israel patent law in litigation in the U.S.A.
Mr. Feigelson has spoken at meetings of the American Chemical Society, of which he is a member, and is active in the Chemical Practice and the Professional Programs Committees of the American Intellectual Property Law Association, of which he is also a member. Mr. Feigelson has also been of counsel to an intellectual property law firm in the U.S., an association which included a 6-month sabbatical in the firm’s office in New York.
An American who has resided in Israel since 1990, Mr. Feigelson has degrees in Chemistry from Princeton University (A.B. cum laude) and the Weizmann Institute (M.Sc.), where his theses focused respectively on synthetic organic chemistry and the elucidation of antibody-antigen interactions by NMR. He also has a law degree from Tel-Aviv University (LL.B.). He is registered to practice before the U.S. and Israel patent offices and is admitted to the bars of New York and Israel. When he is not helping clients protect their intellectual property rights, he can be found reading with his children, hiking in national parks or playing as an extra French horn with the Jerusalem Symphony.